Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study

Osteoporosis International

Volumn 21, Issue 9, 2010, Pages 1565-1571

  Kaji, H ^a   Kuroki, Y ^b   Murakawa, Y ^c   Funakawa, I ^d   Funasaka, Y ^a   Kanda, F ^e   Sugimoto, T ^c  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kobe Century Memorial Hospital   (Japan)

^c SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^d National Hospital Organization Hyogo Chuo National Hospital   (Japan)

^e KOBE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; OSTEOCALCIN; PARATHYROID HORMONE; PREDNISOLONE; TELOPEPTIDE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CATABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL;

ADULT; AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PARATHYROID HORMONE; PREDNISOLONE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77956494169     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1110-z     Document Type: Article

References (33)

1. Sambrook P, Birmingham J, Kempler S et al (1990) Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 5:1211-1216
2. Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000 (Pubitemid 30350061)
3. Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787
4. Van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224-3229
5. Steinbuch M, Youket TE, Cohen S (2004) Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 15:323-328
6. Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893-899 (Pubitemid 41103445)
7. Kaji H, Sugimoto T, Kanatani M et al (1997) Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. J Bone Miner Res 12:734-741
8. Iu MF, Kaji H, Sowa H et al (2005) Dexamethasone suppresses Smad3 pathway in osteoblastic cells. J Endocrinol 185:131-138
9. Mazziotti G, Angeli A, Bilezikian JP et al (2006) Glucocorticoidinduced osteoporosis: an update. Trends Endocrinol Metab 17:144-149
10. Canalis E, Mazziotti G, Giustina A et al (2007) Glucocorticoidinduced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328
11. Kaji H, Yamauchi M, Chihara K et al (2008) Glucocorticoid excess affects cortical bone geometry in premenopausal, but not postmenopausal women. Calcif Tissue Int 82:182-190
12. Kaji H, Yamauchi M, Chihara K et al (2008) Relationship between endogenous parathyroid hormone and bone metabolism/geometry in female patients treated with glucocorticoid. Horm Metab Res 40:60-65
13. Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
14. Cranney A, Wells G, Willan A et al (2002) Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508-516 (Pubitemid 34925644)
15. Cranney A, Tugwell P, Adachi J et al (2002) Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517-523 (Pubitemid 34925645)
16. Kaji H, Hisa I, Inoue Y et al (2009) Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis. J Bone Miner Metab 27:76-82
17. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082
18. Hochberg MC, Thompson DE, Black DM et al (2005) Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 20:971-976
19. Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299
20. Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. A randomized, double-blind, placebo-controlled extension trial. Arthr Rheumat 44:202-211
21. Amin S, Lavalley MP, Simms RW et al (2002) The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 17:1512-1526
22. Parker CR, Blackwell PJ, Fairbairn KJ et al (2002) Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 87:4482-4489
23. Nawata H, Soen S, Takayanagi R et al (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research. J Bone Miner Metab 23:105-109
24. Shimon I, Eshed V, Doolman R et al (2005) Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporos Int 16:1591-1596
25. de Nijs RNJ, Jacobs JWG, Lems WF et al (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355:675-684
26. Mok CC, Tong KH, To CH et al (2008) Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebocontrolled trial. Osteoporos Int 19:357-364
27. Okada Y, Nawata M, Nakayamada S et al (2008) Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol 35:2249-2254
28. Gomez B, Ardakani S, Ju J et al (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560-1566
29. Blackburn GF, Shah HP, Kenten JH et al (1991) Electrochemiluminescence detection for development of immunoassay and DNA probe assays for clinical diagnosis. Clin Chem 37:1534-1539
30. Woitage HW, Pecherstorfer M, Li Y et al (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14:792-801
31. Kuroki Y, Kaji H, Kawano S et al (2008) Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab 26:271-278
32. Haugeberg G, Griffiths B, Sokoll KB et al (2004) Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis 63:940-944
33. Jacobs JW, de Nijs RN, Lems WF et al (2007) Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of changes in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol 34:1051-1057